Quick Answer
Monopar Therapeutics reported Operating Income Loss of -$16.70 million for the year ending 2025.
- Monopar Therapeutics showed a decrease of -3.4% in Operating Income Loss from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$373.8 thousand | Q2 2017: -$595.0 thousand | Q3 2017: -$14.90 million | Q1 2018: -$897.3 thousand | Q2 2018: -$667.5 thousand | Q3 2018: -$667.5 thousand | Q1 2019: -$1.41 million | Q2 2019: -$932.1 thousand | Q3 2019: -$759.4 thousand | Q1 2020: -$1.14 million | Q2 2020: -$1.46 million | Q3 2020: -$1.65 million | Q1 2021: -$1.89 million | Q2 2021: -$2.09 million | Q3 2021: -$2.46 million | Q1 2022: -$2.46 million | Q2 2022: -$2.76 million | Q3 2022: -$2.41 million | Q1 2023: -$2.53 million | Q2 2023: -$2.33 million | Q3 2023: -$2.07 million | Q1 2024: -$1.72 million | Q2 2024: -$1.79 million | Q3 2024: -$1.57 million | Q1 2025: -$3.22 million | Q2 2025: -$3.23 million | Q3 2025: -$4.09 million.
- Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Operating Income Loss has declined by 1,300.4%.
- Historical annual values: Fiscal year 2025: -$16.70 million | Fiscal year 2024: -$16.16 million | Fiscal year 2023: -$8.83 million | Fiscal year 2022: -$10.54 million | Fiscal year 2021: -$9.13 million | Fiscal year 2020: -$6.51 million | Fiscal year 2019: -$4.32 million | Fiscal year 2018: -$3.33 million | Fiscal year 2017: -$16.60 million | Fiscal year 2016: -$1.19 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: